Acute myeloid leukemia
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. AML manifests by fever, pallor, anemia, hemorrhages and recurrent infections.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Acute myeloid leukemia
- Therapeutic area
- Hematology
- acute myeloid leukemia
- AML
- AML - acute myeloid leukaemia
- AML - acute myeloid leukemia
- ANLL
- acute Nonlymphocytic leukaemia
- acute Nonlymphocytic leukemia
- acute granulocytic leukaemia
- acute granulocytic leukemia
- acute myeloblastic leukemia
- acute myelocytic leukaemia
- acute myelocytic leukemia
- acute myelogenous leukemia
- acute myelogenous leukemias
- acute myeloid leukaemia (AML)
- acute myeloid leukemia
- acute myeloid leukemia (AML)
- acute myeloid leukemia, somatic
- acute nonlymphocytic leukaemia
- acute nonlymphocytic leukemia
- hematopoeitic - acute Myleogenous leukaemia (AML)
- hematopoeitic - acute Myleogenous leukemia (AML)
- leukemia, acute myeloid, autosomal dominant, somatic mutation
- leukemia, acute myeloid, reduced survival in, somatic
- leukemia, acute myeloid, somatic
And 7 more, listed on the interactive page.
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0018874
- Parent condition
- MONDO:0004643
Related records
Broader conditions (31)
- Acute disease
- Acute leukemia
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
Narrower conditions (111)
- Acute basophilic leukemia
- Acute biphenotypic leukemia
- Acute erythroid leukemia
- Acute leukemia of ambiguous lineage
- Acute megakaryoblastic leukemia
- Acute megakaryoblastic leukemia in adult
- Acute megakaryoblastic leukemia in down syndrome
- Acute megakaryoblastic leukemia without down syndrome
- Acute monocytic leukemia
- Acute myeloblastic leukemia with maturation
- Acute myeloblastic leukemia without maturation
- Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
- Acute myeloid leukemia and myelodysplastic syndromes related to radiation
- Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
- Acute myeloid leukemia by FAB classification
- Acute myeloid leukemia with 11q23 abnormalities
- Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
- Acute myeloid leukemia with BCR-ABL1
- Acute myeloid leukemia with CBFA2T3-GLIS2 fusion
- Acute myeloid leukemia with CEBPA somatic mutations
Trials (2,602)
- "InDACtion" vs "3+7" Induction in AML
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
- 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
- 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
- A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
Approved drugs (16)
- Azacitidine
- Cytarabine
- Daunorubicin
- Enasidenib mesylate
- Gemtuzumab ozogamicin
- Gilteritinib fumarate
- Glasdegib maleate
- Histamine dihydrochloride
- Idarubicin hydrochloride
- Ivosidenib
- Melphalan hydrochloride
- Midostaurin
- Olutasidenib
- Quizartinib dihydrochloride
- Sargramostim
- Tagraxofusp
Drugs in development (418)
- 4SC-203 Phase 1
- 8-chloroadenosine Phase 1
- 9-aminocamptothecin Phase 1
- ABBV-744 Phase 1
- Acetaminophen Phase 2
- Acetylcysteine Phase 2
- Aclarubicin Phase 3
- AGS62P1 Phase 1
- AHN-12 Phase 1
- AKN-028 Phase 1
- Aldesleukin Phase 3
- Alemtuzumab Phase 3
- Alisertib Phase 2
- Allopurinol Phase 2
- Alovudine F-18 Phase 2
- Alrizomadlin Phase 1
- Alvocidib Phase 2
- Alvocidib hydrochloride Phase 1
- AMG553 Phase 1
- Amifostine Phase 1
Other linked drugs (6)
- Dasatinib
- Fimepinostat
- Lintuzumab actinium AC-225
- Luveltamab tazevibulin
- MRX-2843
- Naxtarubicin